OBJECTIVE: To test the hypothesis that concentrations of adropin, a recently discovered peptide that displays important metabolic and cardiovascular functions, are lower in obstructive sleep apnea (OSA), especially when associated with endothelial dysfunction. STUDY DESIGN: Age-, sex-, and ethnicity-matched children (mean age, 7.2 ± 1.4 years) were included into 1 of 3 groups based on the presence of OSA in an overnight sleep study, and on the time to postocclusive maximal reperfusion (Tmax >45 seconds) with a modified hyperemic test. Plasma adropin concentrations were assayed using a commercial enzyme-linked immunosorbent assay kit. RESULTS: Among controls, the mean morning adropin concentration was 7.4 ng/mL (95% CI, 5.2-16.3 ng/mL). Children with OSA and abnormal endothelial function (EF) (OSA(+)/EF(+) group) had significantly lower adropin concentrations (2.7 ± 1.1 ng/mL; n = 35) compared with matched controls (7.6 ± 1.4 ng/mL; n = 35; P < .001) and children with OSA and normal EF (OSA(+)/EF(-) group; 5.8 ± 1.5 ng/mL; n = 47; P < .001). A plasma adropin concentration <4.2 ng/mL reliably predicted EF status, but individual adropin concentrations were not significantly correlated with age, body mass index z-score, obstructive apnea-hypopnea index, or nadir oxygen saturation. Mean adropin concentration measured after adenotonsillectomy in a subset of children with OSA (n = 22) showed an increase in the OSA(+)/EF(+) group (from 2.5 ± 1.4 to 6.4 ± 1.9 ng/mL; n = 14; P < .01), but essentially no change in the OSA(+)EF(-) group (from 5.7 ± 1.3 to 6.4 ± 1.1 ng/mL; n = 8; P > .05). CONCLUSION: Plasma adropin concentrations are reduced in pediatric OSA when endothelial dysfunction is present, and return to within normal values after adenotonsillectomy. Assessment of circulating adropin concentrations may provide a reliable indicator of vascular injury in the context of OSA in children.
OBJECTIVE: To test the hypothesis that concentrations of adropin, a recently discovered peptide that displays important metabolic and cardiovascular functions, are lower in obstructive sleep apnea (OSA), especially when associated with endothelial dysfunction. STUDY DESIGN: Age-, sex-, and ethnicity-matched children (mean age, 7.2 ± 1.4 years) were included into 1 of 3 groups based on the presence of OSA in an overnight sleep study, and on the time to postocclusive maximal reperfusion (Tmax >45 seconds) with a modified hyperemic test. Plasma adropin concentrations were assayed using a commercial enzyme-linked immunosorbent assay kit. RESULTS: Among controls, the mean morning adropin concentration was 7.4 ng/mL (95% CI, 5.2-16.3 ng/mL). Children with OSA and abnormal endothelial function (EF) (OSA(+)/EF(+) group) had significantly lower adropin concentrations (2.7 ± 1.1 ng/mL; n = 35) compared with matched controls (7.6 ± 1.4 ng/mL; n = 35; P < .001) and children with OSA and normal EF (OSA(+)/EF(-) group; 5.8 ± 1.5 ng/mL; n = 47; P < .001). A plasma adropin concentration <4.2 ng/mL reliably predicted EF status, but individual adropin concentrations were not significantly correlated with age, body mass index z-score, obstructive apnea-hypopnea index, or nadir oxygen saturation. Mean adropin concentration measured after adenotonsillectomy in a subset of children with OSA (n = 22) showed an increase in the OSA(+)/EF(+) group (from 2.5 ± 1.4 to 6.4 ± 1.9 ng/mL; n = 14; P < .01), but essentially no change in the OSA(+)EF(-) group (from 5.7 ± 1.3 to 6.4 ± 1.1 ng/mL; n = 8; P > .05). CONCLUSION: Plasma adropin concentrations are reduced in pediatric OSA when endothelial dysfunction is present, and return to within normal values after adenotonsillectomy. Assessment of circulating adropin concentrations may provide a reliable indicator of vascular injury in the context of OSA in children.
Authors: K Ganesh Kumar; Jingying Zhang; Su Gao; Jari Rossi; Owen P McGuinness; Heather H Halem; Michael D Culler; Randall L Mynatt; Andrew A Butler Journal: Obesity (Silver Spring) Date: 2012-02-09 Impact factor: 5.002
Authors: Andrew A Butler; Charmaine S Tam; Kimber L Stanhope; Bruce M Wolfe; Mohamed R Ali; Majella O'Keeffe; Marie-Pierre St-Onge; Eric Ravussin; Peter J Havel Journal: J Clin Endocrinol Metab Date: 2012-08-07 Impact factor: 5.958
Authors: Joseph A Crisalli; Keith McConnell; Rhonda D Vandyke; Matthew C Fenchel; Virend K Somers; A Shamszumann; Barbara Chini; Stephen R Daniels; Raouf S Amin Journal: Sleep Date: 2012-10-01 Impact factor: 5.849
Authors: Rosemary S C Horne; Joel S C Yang; Lisa M Walter; Heidi L Richardson; Denise M O'Driscoll; Alison M Foster; Shi Wong; Michelle L Ng; Farhat Bashir; Ruth Patterson; Gillian M Nixon; Damien Jolley; Adrian M Walker; Vicki Anderson; John Trinder; Margot J Davey Journal: Pediatrics Date: 2011-06-27 Impact factor: 7.124
Authors: Graziela De Luca Canto; Camila Pachêco-Pereira; Secil Aydinoz; Paul W Major; Carlos Flores-Mir; David Gozal Journal: Sleep Med Rev Date: 2014-11-28 Impact factor: 11.609
Authors: Joseph R Stevens; Monica L Kearney; Marie-Pierre St-Onge; Kimber L Stanhope; Peter J Havel; Jill A Kanaley; John P Thyfault; Edward P Weiss; Andrew A Butler Journal: Obesity (Silver Spring) Date: 2016-08 Impact factor: 5.002